Literature DB >> 15192276

CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan.

Ichiro Konishi1, Norio Horiike, Yoichi Hiasa, Kojiro Michitaka, Morikazu Onji.   

Abstract

OBJECTIVE: Chemokines and chemokine receptors play important roles in the pathogenesis of chronic hepatitis C. Here, we explore the influence of genetic polymorphisms of chemokine and chemokine receptors such as regulated upon activation and T cell secreted (RANTES), CC chemokine receptor 5 (CCR5) and CCR2 on the outcome of interferon (IFN) monotherapy.
METHODS: In a cohort of 105 patients with chronic hepatitis C as well as in 50 sustained responders and 55 nonresponders the presence of polymorphisms such as CCR5-Delta32, CCR5 59029G/A, CCR2 V64I and RANTES -403G/C was determined.
RESULTS: Gender, age, liver histological staging, pretreatment ALT levels, total dose of IFN and frequencies of polymorphisms (CCR2 V64I and RANTES -403G/C) did not significantly differ between the two groups. A low viral load, hepatitis C virus (HCV) serotype 2 and CCR5 59029G/G were significantly associated with a higher probability of a sustained response (p < 0.01, p < 0.05, p < 0.05, respectively). Multiple logistic regression analysis showed that a low viral load, HCV serotype 2 and CCR5 59029G/G were independently associated with a sustained response [odds ratio 3.980 (1.647-9.621), p = 0.002; 3.584 (1.439-8.924), p = 0.006; 3.638 (1.163-11.379), p = 0.026, respectively].
CONCLUSION: These findings indicate that CCR5 59029 is a host genetic factor that is associated with responses to IFN therapy among Japanese patients with chronic hepatitis C. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15192276     DOI: 10.1159/000077835

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  11 in total

1.  Concordance of CCR5 genotypes that influence cell-mediated immunity and HIV-1 disease progression rates.

Authors:  Gabriel Catano; Zoya A Chykarenko; Andrea Mangano; J-M Anaya; Weijing He; Alison Smith; Rosa Bologna; Luisa Sen; Robert A Clark; Andrew Lloyd; Ludmila Shostakovich-Koretskaya; Sunil K Ahuja
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

2.  CCR2-64I allele is associated with the progression of AIDS in a Han Chinese population.

Authors:  Lidan Xu; Yuandong Qiao; Xuelong Zhang; Haiming Sun; Jingwei Wang; Donglin Sun; Yan Jin; Yang Yu; Feng Chen; Jing Bai; Hong Ling; Kaili Wang; Songbin Fu
Journal:  Mol Biol Rep       Date:  2009-08-08       Impact factor: 2.316

3.  CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C.

Authors:  Ankur Goyal; P V Suneetha; G T Kumar; Deepak K Shukla; Naveen Arora; Shiv K Sarin
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

4.  Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis.

Authors:  Pierre Nahon; Angela Sutton; Pierre Rufat; Chantal Simon; Jean-Claude Trinchet; Liliane Gattegno; Michel Beaugrand; Nathalie Charnaux
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

5.  Evolution of interferon-based therapy for chronic hepatitis C.

Authors:  Chun-Hao Chen; Ming-Lung Yu
Journal:  Hepat Res Treat       Date:  2010-10-10

6.  CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population.

Authors:  M-A Montes-Cano; J-R Garcia-Lozano; J Aguilar-Reina; M Romero-Gomez; N Barroso; A Nunez-Roldan; M-F Gonzalez-Escribano
Journal:  World J Gastroenterol       Date:  2007-04-21       Impact factor: 5.742

7.  A Study of CC-Chemokine Receptor 5 (CCR5) Polymorphism on the Outcome of HCV Therapy in Egyptian Patients.

Authors:  Moataza H Omran; Mahmoud Khamis; Nada Nasr; Ahmed A Massoud; Samar S Youssef; Noha G Bader El Din; Reham M Dawood; Khaled Atef; Rehab I Moustafa; Wael Nabil; Ashraf A Tabll; Mostafa K El Awady
Journal:  Hepat Mon       Date:  2013-12-19       Impact factor: 0.660

8.  A Study on the Association between CCRΔ32 Mutation and HCV Infection in Iranian Patients.

Authors:  Farahnaz Bineshian; Asieh Hosseini; Zohre Sharifi; Afsaneh Aghaie
Journal:  Avicenna J Med Biotechnol       Date:  2018 Oct-Dec

9.  Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants.

Authors:  Francesc Vidal; Miguel López-Dupla; Montserrat Laguno; Sergi Veloso; Josep Mallolas; Javier Murillas; Carmen Cifuentes; Lluis Gallart; Teresa Auguet; Gloria Sampériz; Antoni Payeras; Pilar Hernandez; Mireia Arnedo; Josep Ma Gatell; Cristóbal Richart
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

10.  CCR5 haplotypes influence HCV serostatus in Caucasian intravenous drug users.

Authors:  Kristi Huik; Radko Avi; Andrew Carrillo; Nathan Harper; Merit Pauskar; Maarja Sadam; Tõnis Karki; Tõnu Krispin; Ulvi-Kaire Kongo; Tatiana Jermilova; Kristi Rüütel; Ave Talu; Katri Abel-Ollo; Anneli Uusküla; Sunil K Ahuja; Weijing He; Irja Lutsar
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.